Actualités Mast Therapeutics, Inc. - ANX | Actions American Stock Exchange

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Mast Therapeutics Initiates Sub-Study Within Phase 3 EPIC Trial

Mast Therapeutics Initiates Sub-Study Within Phase 3 EPIC Trial Sub-study will investigate effects of MST-188 on tissue oxygenation in sickle...

Mast Therapeutics Announces New Data Supporting MST-188 In Sickle Cell Disease

Mast Therapeutics Announces New Data Supporting MST-188 In Sickle Cell Disease MST-188 decreased a marker of inflammation and red blood cell...

Mast Therapeutics Signs Definitive Agreement To Acquire Aires Pharmaceuticals, Inc.

Mast Therapeutics Signs Definitive Agreement To Acquire Aires Pharmaceuticals, Inc. - All-stock transaction - Conference call to discuss pending...

Mast Therapeutics To Present At The Rodman & Renshaw 15th Annual Healthcare Conference On September 10

Mast Therapeutics To Present At The Rodman & Renshaw 15th Annual Healthcare Conference On September 10 PR Newswire SAN DIEGO, Sept. 3, 2013...

ADVENTRX Completes Name Change To "Mast Therapeutics, Inc."; New Ticker Symbol: "MSTX"

ADVENTRX Completes Name Change To "Mast Therapeutics, Inc."; New Ticker Symbol: "MSTX" PR Newswire SAN DIEGO, March 11, 2013...

Current Report Filing (8-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM...

ADVENTRX Announces Corporate Name Change To "Mast Therapeutics, Inc."; Ticker Symbol Change To "MSTX"

ADVENTRX Announces Corporate Name Change To "Mast Therapeutics, Inc."; Ticker Symbol Change To "MSTX" Name and ticker symbol...

Adventrx To Develop ANX-188 For Complications Of Arterial Disease

Adventrx To Develop ANX-188 For Complications Of Arterial Disease - Seeking orphan drug designation in acute limb ischemia (ALI) - Phase 2...

Current Report Filing (8-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM...

ADVENTRX Reviews Data Supporting Development Of ANX-188 In New Indications

ADVENTRX Reviews Data Supporting Development Of ANX-188 In New Indications - Platform includes over 100 pharmacology studies, 15 clinical studies...

ADVENTRX To Present At The Cowen And Company 33rd Annual Health Care Conference On March 4

ADVENTRX To Present At The Cowen And Company 33rd Annual Health Care Conference On March 4 PR Newswire SAN DIEGO, Feb. 25, 2013 SAN DIEGO, Feb...

ADVENTRX Initiates Thorough QT/QTc Clinical Study Of ANX-188

ADVENTRX Initiates Thorough QT/QTc Clinical Study Of ANX-188 PR Newswire SAN DIEGO, Feb. 11, 2013 SAN DIEGO, Feb. 11, 2013 /PRNewswire/...

Current Report Filing (8-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM...

ADVENTRX To Present At The 15th Annual BIO CEO & Investor Conference On February 12

ADVENTRX To Present At The 15th Annual BIO CEO & Investor Conference On February 12 /* Style Definitions */ span.prnews_span { font-size:8p...

ADVENTRX Initiates Pivotal Phase 3 Study of ANX-188

ADVENTRX Initiates Pivotal Phase 3 Study of ANX-188 /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black;...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Mast Therapeutics, Inc. (ANX)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

ANX Actualités

Mast Therapeutics Initiates Sub-Study Within Phase 3 EPIC Trial

Mast Therapeutics Announces New Data Supporting MST-188 In Sickle Cell Disease

Mast Therapeutics Signs Definitive Agreement To Acquire Aires Pharmaceuticals, Inc.

Mast Therapeutics To Present At The Rodman & Renshaw 15th Annual Healthcare Conference On September 10

ADVENTRX Completes Name Change To "Mast Therapeutics, Inc."; New Ticker Symbol: "MSTX"

Current Report Filing (8-k)

ADVENTRX Announces Corporate Name Change To "Mast Therapeutics, Inc."; Ticker Symbol Change To "MSTX"

Adventrx To Develop ANX-188 For Complications Of Arterial Disease

Current Report Filing (8-k)

ADVENTRX Reviews Data Supporting Development Of ANX-188 In New Indications

ADVENTRX To Present At The Cowen And Company 33rd Annual Health Care Conference On March 4

ADVENTRX Initiates Thorough QT/QTc Clinical Study Of ANX-188

Current Report Filing (8-k)

ADVENTRX To Present At The 15th Annual BIO CEO & Investor Conference On February 12

ADVENTRX Initiates Pivotal Phase 3 Study of ANX-188

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Mast Therapeutics, Inc. (ANX) Actualités

Mast Therapeutics, Inc. (ANX)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

ANX Actualités

Mast Therapeutics Initiates Sub-Study Within Phase 3 EPIC Trial

Mast Therapeutics Announces New Data Supporting MST-188 In Sickle Cell Disease

Mast Therapeutics Signs Definitive Agreement To Acquire Aires Pharmaceuticals, Inc.

Mast Therapeutics To Present At The Rodman & Renshaw 15th Annual Healthcare Conference On September 10

ADVENTRX Completes Name Change To "Mast Therapeutics, Inc."; New Ticker Symbol: "MSTX"

Current Report Filing (8-k)

ADVENTRX Announces Corporate Name Change To "Mast Therapeutics, Inc."; Ticker Symbol Change To "MSTX"

Adventrx To Develop ANX-188 For Complications Of Arterial Disease

Current Report Filing (8-k)

ADVENTRX Reviews Data Supporting Development Of ANX-188 In New Indications

ADVENTRX To Present At The Cowen And Company 33rd Annual Health Care Conference On March 4

ADVENTRX Initiates Thorough QT/QTc Clinical Study Of ANX-188

Current Report Filing (8-k)

ADVENTRX To Present At The 15th Annual BIO CEO & Investor Conference On February 12

ADVENTRX Initiates Pivotal Phase 3 Study of ANX-188

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités